Despite targeted efforts to reduce obesity through diet and exercise, these rates continue to rise. A new study from Ontario, Canada found that obesity and diabetes rates were lower in more walkable neighborhoods compared to less walkable neighborhoods, where they saw an increase in these rates.
Researchers from St. Michael's Hospital in Toronto studied almost 9,000 neighborhoods in Southern Ontario looking at walkability scores, along with government health data and survey results during a twelve-year period. They examined whether neighborhoods that were more walkable experienced a slower increase in obesity and diabetes compared to less walkable neighborhoods.
Rates of Obesity and Diabetes Lower in More Walkable Neighborhoods
A study found neighborhoods that were more walkable experienced a slower increase in obesity and diabetes compared to less walkable neighborhoods.
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
In Partnership with
Overview
Recommended
Details
In Partnership with
Overview
Despite targeted efforts to reduce obesity through diet and exercise, these rates continue to rise. A new study from Ontario, Canada found that obesity and diabetes rates were lower in more walkable neighborhoods compared to less walkable neighborhoods, where they saw an increase in these rates.
Researchers from St. Michael's Hospital in Toronto studied almost 9,000 neighborhoods in Southern Ontario looking at walkability scores, along with government health data and survey results during a twelve-year period. They examined whether neighborhoods that were more walkable experienced a slower increase in obesity and diabetes compared to less walkable neighborhoods.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE Broadcast Replay
Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease
1.00 credits
<p>Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease</p>
CME/CE Broadcast Replay
Love Story: Lipid Education for Women’s Heart Health
0.50 credits
<p>Love Story: Lipid Education for Women’s Heart Health</p>
MinuteCE®
Level Up Your Skills: Tailoring Management of HF
0.75 credits
<p>Level Up Your Skills: Tailoring Management of HF</p>
MinuteCE®
Clinical Conundrums in ARIA: 1. Navigating the Baseline MRI for Anti-Aβ Monoclonal Antibodies
1.25 credits
<p>Clinical Conundrums in ARIA: Navigating the Baseline MRI for Anti-Aβ Monoclonal Antibodies</p>
MinuteCE®
Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy
1.25 credits
<p>Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy</p>
NeuroFrontiers
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
<p>Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids</p>
Cardiology
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
<p>Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF</p>
Cardiology
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
<p>Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?